Sorrento Therapeutics Inc. (SRNE): Price and Financial Metrics

Sorrento Therapeutics Inc. (SRNE): $1.62

0.08 (+5.19%)

POWR Rating

Component Grades













Add SRNE to Watchlist
Sign Up

Industry: Biotech



in industry


  • Quality is the dimension where SRNE ranks best; there it ranks ahead of 38.92% of US stocks.
  • The strongest trend for SRNE is in Growth, which has been heading down over the past 179 days.
  • SRNE ranks lowest in Sentiment; there it ranks in the 5th percentile.

SRNE Stock Summary

  • SRNE's price/sales ratio is 16.11; that's higher than the P/S ratio of 91.19% of US stocks.
  • In terms of volatility of its share price, SRNE is more volatile than 92.61% of stocks we're observing.
  • Sorrento Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -21.27%, greater than the shareholder yield of only 17.48% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Sorrento Therapeutics Inc, a group of peers worth examining would be QLGN, POWI, NVTA, PROF, and TXG.
  • Visit SRNE's SEC page to see the company's official filings. To visit the company's web site, go to

SRNE Valuation Summary

  • SRNE's price/earnings ratio is -8.4; this is 123.01% lower than that of the median Healthcare stock.
  • Over the past 145 months, SRNE's price/sales ratio has gone NA NA.
  • Over the past 145 months, SRNE's EV/EBIT ratio has gone up 399.

Below are key valuation metrics over time for SRNE.

Stock Date P/S P/B P/E EV/EBIT
SRNE 2021-08-31 52.6 14.4 -8.4 -8.9
SRNE 2021-08-30 51.8 14.2 -8.3 -8.8
SRNE 2021-08-27 53.5 14.7 -8.5 -9.1
SRNE 2021-08-26 52.8 14.5 -8.4 -9.0
SRNE 2021-08-25 54.5 14.9 -8.7 -9.2
SRNE 2021-08-24 53.2 14.6 -8.5 -9.0

SRNE Growth Metrics

    The 3 year net cashflow from operations growth rate now stands at -147.37%.
  • Its 2 year cash and equivalents growth rate is now at 176.05%.
  • The year over year price growth rate now stands at 161.43%.
SRNE's revenue has moved up $17,364,000 over the prior 18 months.

The table below shows SRNE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 52.904 -281.821 -428.325
2021-09-30 51.333 -250.553 -355.41
2021-06-30 51.024 -210.033 -319.63
2021-03-31 46.52 -169.043 -230.755
2020-12-31 39.986 -159.536 -298.461
2020-09-30 41.515 -154.689 -289.778

SRNE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SRNE has a Quality Grade of D, ranking ahead of 18.46% of graded US stocks.
  • SRNE's asset turnover comes in at 0.081 -- ranking 278th of 681 Pharmaceutical Products stocks.
  • VBLT, ISEE, and CNCE are the stocks whose asset turnover ratios are most correlated with SRNE.

The table below shows SRNE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.081 0.770 -0.709
2021-03-31 0.081 0.766 -0.448
2020-12-31 0.072 0.751 -0.573
2020-09-30 0.074 0.788 -0.513
2020-06-30 0.065 0.681 -0.446
2020-03-31 0.059 0.625 -0.388

SRNE Price Target

For more insight on analysts targets of SRNE, see our SRNE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.67 Average Broker Recommendation 1.5 (Moderate Buy)

SRNE Stock Price Chart Interactive Chart >

Price chart for SRNE

SRNE Price/Volume Stats

Current price $1.62 52-week high $11.07
Prev. close $1.54 52-week low $1.15
Day low $1.50 Volume 9,376,100
Day high $1.63 Avg. volume 8,536,588
50-day MA $1.85 Dividend yield N/A
200-day MA $4.72 Market Cap 630.09M

Sorrento Therapeutics Inc. (SRNE) Company Bio

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.

SRNE Latest News Stream

Event/Time News Detail
Loading, please wait...

SRNE Latest Social Stream

Loading social stream, please wait...

View Full SRNE Social Stream

Latest SRNE News From Around the Web

Below are the latest news stories about Sorrento Therapeutics Inc that investors may wish to consider to help them evaluate SRNE as an investment opportunity.

Zymeworks Inc. (ZYME) Reports Q4 Loss, Tops Revenue Estimates

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 10.38% and 56.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Sorrento Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses

STI-9167 neutralizing antibody (nAb) maintains high neutralization potency against the recently emerging Omicron sublineage BA.2 as was previously demonstrated for the Omicron sublineage BA.1 viruses, including Omicron BA.1 (+R346K mutation).An IND application for COVISHIELD™ IN, formulated for intranasal (IN) administration for clinical use in the context of early symptomatic and asymptomatic infections, was submitted to the FDA on February 1, 2022. SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) --

Yahoo | February 22, 2022

Sorrento acquires a majority stake in FortuneBio to meet demand for rapid COVID-19 test

Sorrento Therapeutics (NASDAQ:SRNE) announced the acquisition of Chinese-based diagnostic test maker, Zhengzhou Fortune Bioscience as the company plans to ramp up the production of its COVISTIX COVID-19 VIRUS Rapid Antigen Detection Test. The deal includes an option for Sorrento (SRNE) to acquire 100% of the company. The financial terms of...

Seeking Alpha | February 17, 2022

Sorrento Announces That It Has Acquired a Majority Ownership in Diagnostic Manufacturer Zhengzhou Fortune Bioscience in Response to Increasing Worldwide Demand For COVISTIX™

COVISTIX is a highly sensitive and rapid antigen detection test for SARS-CoV-2 and its major variants of concern (VOCs), including the Omicron variant.COVISTIX has an enhanced sensitivity in detecting the Omicron variant with a more than 10-fold lower limit of detection (LoD) as compared to that of the original SAR-CoV-2 strain.COVISTIX has been approved for emergency use and is on the market in Brazil and Mexico, and is CE marked for sale in Europe for professional point-of-care use.In response

Yahoo | February 17, 2022

Analysts Estimate Sorrento Therapeutics (SRNE) to Report a Decline in Earnings: What to Look Out for

Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 11, 2022

Read More 'SRNE' Stories Here

SRNE Price Returns

1-mo 1.25%
3-mo -37.45%
6-mo -72.50%
1-year -78.46%
3-year -45.08%
5-year -7.43%
YTD -65.16%
2021 -31.87%
2020 101.92%
2019 40.83%
2018 -36.84%
2017 -22.45%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7979 seconds.